Abstract
Tumor angiogenesis imaging should provide non-invasive assays of tumor vascular characteristics to supplement the now conventional diagnostic imaging goals of depicting tumor location, size, and morphology. This article will review the current status of angiogenesis imaging approaches, considering ultrasound, CT, MR, SPECT, PET and optical techniques with attention to their respective capabilities and limitations. As a group, these imaging methods have some potential to depict and quantify tumor microvascular features, including those considered to be functionally associated with tumor angiogenesis. Additionally, new molecule-specific imaging techniques may serve to depict those biochemical pathways and regulatory events that control blood vessel growth and proliferation. Non-invasive monitoring of anti-angiogenic therapies has great appeal and should find wide application for defining tumor microvascular and metabolic changes, because treatment-related changes in tumor morphology tend to occur rather late and are non-specific. Future developments are likely to include "fusion" or "hybrid" imaging methods. Superimposed data from MR imaging with spectroscopy, PET with CT, and PET with MR should be able to integrate advantages of different modalities yielding comprehensive information about tumor structure, function and microenvironment.
Keywords: Macromolecular contrast agents, blood pool agents, Angiogenesis Imaging
Current Pharmaceutical Design
Title: Imaging of Tumor Angiogenesis: Current Approaches and Future Prospects
Volume: 12 Issue: 21
Author(s): Heike E. Daldrup-Link, Gerhard H. Simon and Robert C. Brasch
Affiliation:
Keywords: Macromolecular contrast agents, blood pool agents, Angiogenesis Imaging
Abstract: Tumor angiogenesis imaging should provide non-invasive assays of tumor vascular characteristics to supplement the now conventional diagnostic imaging goals of depicting tumor location, size, and morphology. This article will review the current status of angiogenesis imaging approaches, considering ultrasound, CT, MR, SPECT, PET and optical techniques with attention to their respective capabilities and limitations. As a group, these imaging methods have some potential to depict and quantify tumor microvascular features, including those considered to be functionally associated with tumor angiogenesis. Additionally, new molecule-specific imaging techniques may serve to depict those biochemical pathways and regulatory events that control blood vessel growth and proliferation. Non-invasive monitoring of anti-angiogenic therapies has great appeal and should find wide application for defining tumor microvascular and metabolic changes, because treatment-related changes in tumor morphology tend to occur rather late and are non-specific. Future developments are likely to include "fusion" or "hybrid" imaging methods. Superimposed data from MR imaging with spectroscopy, PET with CT, and PET with MR should be able to integrate advantages of different modalities yielding comprehensive information about tumor structure, function and microenvironment.
Export Options
About this article
Cite this article as:
Daldrup-Link E. Heike, Simon H. Gerhard and Brasch C. Robert, Imaging of Tumor Angiogenesis: Current Approaches and Future Prospects, Current Pharmaceutical Design 2006; 12 (21) . https://dx.doi.org/10.2174/138161206777698774
DOI https://dx.doi.org/10.2174/138161206777698774 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alpha-Interferon and Its Effects on Signalling Pathways Within Cells
Current Protein & Peptide Science Involvement of the P2X7 Purinergic Receptor in Inflammation: An Update of Antagonists Series Since 2009 and their Promising Therapeutic Potential
Current Medicinal Chemistry PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention
Current Medicinal Chemistry Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies
Current Cancer Drug Targets Anticancer Mechanisms of Berberine: A Good Choice for Glioblastoma Multiforme Therapy
Current Medicinal Chemistry Rate Limiting Steps of AAV Transduction and Implications for Human Gene Therapy
Current Gene Therapy Nanoparticles in Melanoma
Current Medicinal Chemistry Metastasis-Inducing S100A4 Protein: Implication in Non-Malignant Human Pathologies
Current Molecular Medicine Nanoscale Formulations and Diagnostics With Their Recent Trends: A Major Focus of Future Nanotechnology
Current Pharmaceutical Design Imaging Adoptive Cell Transfer Based Cancer Immunotherapy
Current Pharmaceutical Biotechnology Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
Current Cancer Drug Targets Emerging Roles of microRNAs in the Molecular Responses to Hypoxia
Current Pharmaceutical Design Endothelial Cell Targeted Molecular Imaging in Tumor Angiogenesis: Strategies and Current Status
Current Pharmaceutical Biotechnology Cellular Targets for Anticancer Strategies
Current Drug Targets Rational Drug Design of G-Quartet DNA as Anti-Cancer Agents
Current Pharmaceutical Design Antibody-Onconase Conjugates: Cytotoxicity and Intracellular Routing
Current Pharmaceutical Biotechnology Cannabinoid Receptors as Therapeutic Targets
Current Pharmaceutical Design Passive Targeting of Cyclophosphamide-Loaded Carbonate Apatite Nanoparticles to Liver Impedes Breast Tumor Growth in a Syngeneic Model
Current Pharmaceutical Design Tumour Mutation Profiling with High-throughput Multiplexed Genotyping: A Review of its Use for Guiding Targeted Cancer Therapy
Current Cancer Therapy Reviews Emerging Concepts in the Analysis of Mitochondrial Genome Instability
Current Genomics